drugset / Trial / NCT03710252
A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND Study
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase IV, open label, single center study of OBV/PTV/r + DSV +/- RBV for 12 or 24 weeks for the treatment of chronic HCV-1 infection in a real world urban clinical setting.
Timeline
- Start
- 2016-03
- Primary completion
- 2017-09
- Completion
- 2017-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ribavirin | Small molecule | — | — |
| Subject | Ritonavir | Other / unclassified | — | — |
| Subject | dasabuvir | Small molecule | — | — |
| Subject | ombitasvir | Small molecule | — | — |
| Subject | paritaprevir | Small molecule | — | — |